Inflammatory Twins from PI3K Gang Brought to Justice?  by Thompson, Philip E. et al.
Chemistry & Biology
PreviewsInflammatory Twins from PI3K Gang
Brought to Justice?Philip E. Thompson,1,* Ian G. Jennings,1 and Jo-Anne Pinson1
1Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Australia
*Correspondence: philip.thompson@pharm.monash.edu.ac
DOI 10.1016/j.chembiol.2010.02.001
PI3 kinase inhibitors are hot property. In this issue of Chemistry & Biology, Williams et al. add a dual PI3Kd/g
inhibitor to the collection and show that its anti-inflammatory profile in vitro is quite different from pan-PI3K
inhibitors, but bears an uncanny resemblance to that of the glucocorticoid drugs.In 2007, Rommel et al. suggested that
PI3Kd and PI3Kg were partners in crime
in inflammation—working in concert and
terrorizing our immune systems like
cellular versions of Monty Python’s Lon-
don gangsters, the cruel-but-fair Piranha
Brothers (http://www.ethelthefrog.com/
?tag=youtube). Williams et al. (2010)
describe the compound SW14, their
version of the determined Superintendent
Harry ‘‘Snapper’’ Organs, single-hand-
edly bringing down these kinase twins,
compiling a broad dossier of evidence
against them, and foreshadowing an
exciting approach to treating inflamma-
tory and immunological diseases.
From the first identification of PI3
kinase as a fundamental component of
cell signaling, PI3K inhibitors have been
postulated as drugs of the future for treat-
ing a range of disease states. In particular,
the first generation inhibitors wortmannin
and LY294002 were shown to block the
oxidative burst after neutrophils were
treated with fMLP, which identified PI3K
as a potential target for inflammatory
and immunomodulatory diseases (Arcaro
and Wymann, 1993; Vlahos et al., 1995).
In the intervening years, progress across
the field has included the elucidation of
PI3K isoform structures and localization,
and the development of genetic and
pharmacological systems that define the
pathways regulated by PI3K isoforms
(Hirsch et al., 2008). By 2003, both PI3Kg
and PI3Kd (or Doug and Dinsdale) had
been identified as validated drug targets
in immune and inflammatory disease
(Rommel et al., 2007).
Further studies have shown that the
PI3Kg and PI3Kd isoforms have overlap-
ping but nonredundant roles in the inflam-
matory response, and the leap to dual
selectivity inhibitors that do not touch themore widespread PI3Ka and PI3Kb
isoforms was an attractive next step—
attractive but not necessarily simple.
Previously developed PI3K inhibitors had
either modest selectivity or tend to cluster
along PI3Ka/g and PI3Kb/d lines (Knight
et al., 2006). However, in 2006, Shokat’s
and Williams’ groups were able to co-
crystallize a delta selective compound,
PIK39, into the PI3Kg gamma catalytic
domain, revealing an extraordinary alter-
ation in the binding site to accommodate
a bulky quinazoline structure (Figure 1)
(Knight et al., 2006). Thedetective’s hunch
was that the same shift, centered on a
methionine residue, occurs and is favored
in PI3Kd, explaining the remarkable se-
lectivity of IC87114 and analogs (Sadhu
et al., 2003). Further, they asserted that
dual selectivity PI3Kd/g inhibitors would
be achievable by rational design. In this
article, the synthetic achievement and
the demonstrable selectivity are de-
scribed (Williams et al., 2010). For what
must have been a thrilling confirmation of
the design principle, the X-ray structure
of this family in thePI3Kd isoformmatched
their prediction precisely. In compounds
such as SW14, they had the tool to eval-
uate the effects of combined PI3Kd/g
inhibition in comparison to pan-PI3K
and PI3Kd-only inhibitors (Berndt et al.,
2010). In the first set of in vitro experi-
ments, they confirmed the PI3Kd activity
associated withmacrophage colony stim-
ulating factor (M-CSF/CSF-1) action on
THP-1 monocytes and the PI3Kg activity
associated with chemokine, monocyte
chemoattractant protein-1 (MCP-1) con-
firming the selectivity profile of these
compounds in a cellular context.
In many such stories, the next stop is at
in vivo animalmodels, but the authors next
took an unconventional step, subjectingChemistry & Biology 17, February 26, 2010the compounds to a battery of in vitro
assays using the proprietry BioMAP
system from BioSeek (Biologically Multi-
plexed Activity Profiling), importantly
using primary human cell preparations. In
this approach, combinations of primary
cell types are simultaneously activated to
replicate intricate cell and pathway inter-
actions normally found in disease physi-
ology (Kunkel et al., 2004). In this profiling
approach, human umbilical vein endothe-
lial cells (HUVECs), alone or in combina-
tion with peripheral blood mononuclear
cells (PBMCs), are stimulated with various
inflammatory signaling molecules (IL-1b,
TNFa, IFN-g, IL-4, histamine, lipopoly-
saccharide, and Superantigen), with 40
different readouts (mainly ELISA-derived
levels of receptors, cytokines, cell adhe-
sion molecules, and second messengers)
collected and compared to other com-
pounds of other classes. Thankfully, in
this case the results cluster into digestible
pieces; the studies show that the most
effective and T-cell selective inhibitors of
inflammatory signals inhibit both PI3Kd
and PI3Kg, but not PI3Ka and PI3Kb.
Dual targeting of PI3Kd/g resulted
effective inhibition of LPS-induced TNFa
production and overall T cell activation.
Particularly notable was the diminution
of E-selectin production upon Superanti-
gen treatment. PI3Kd inhibition yielded
similar but less efficacious results. Pan-
PI3K inhibition (PIK90) was highly antipro-
liferative to both HUVECs and PMBCs,
but somewhat surprisingly yielded a rela-
tively diminished action on T cells com-
pared to inhibition of PI3Kd/g. The authors
speculate on themechanismof the PI3Kd/
g pathway, noting recently identified
links between PI3Kg and PDE4 signaling
and the identified role of PDE4 inhibition
in TNFa production, but the questionª2010 Elsevier Ltd All rights reserved 101
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Figure 1. Crystal Structures of PI3K-Inhibitor Complexes
Poses of PI3K inhibitors in PI3Kg and PI3Kd showing (A) typical PI3K binding site conformer: LY294002 in
PI3Kg (PDB code: 1E7V), and (B-E) showing induced pocket adjacent to methionine: (B) PIK39 in PI3Kg
(2CHW); (C) PIK39 in PI3Kd (2WXF); (D) IC87114 in PI3Kd (2WXE); (E) SW14 in PI3Kd (2WXH). Images
were generated using Pymol.
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apparent inhibition of this effect by
additional PI3Ka/b inhibition shows the
complexity of even this refined inflamma-
tory cell system.
Last but not least, the authors asked
if the anti-inflammatory signature is remi-
niscent of other anti-inflammatory drugs.
Direct comparison of the profiles of
SW14, SW18, and prednisolone showed
significant similarities, especially with re-
gard to their effect on TNFa production
in the LPS-stimulated HUVEC/PBMC co-
culture. The BioMAP profiles for each
compoundwereanalyzedusingaPearson
correlation metric and visualized in two
dimensions through a multi-dimensional
scaling algorithm. Strikingly, compounds
with significant activity against PI3Kd/g102 Chemistry & Biology 17, February 26, 201(SW14, SW18) were functionally linked to
the glucocorticoid prednisolone. Remark-
ably, in this profiling the PI3Kd/g inhibitors
are more similar to prednisolone than
they are similar to pan-PI3K compounds,
which themselves grouped with inhibitors
mTOR, microtubule modulators, and
estrogens, all of which have been linked
to PI3K in other contexts. Interestingly,
a similar link with prednisolone was previ-
ously observed in studies of PDE4 inhibi-
tors and prednisolone (Kunkel et al.,
2004). The demonstrated efficacy of pred-
nisolone and the advanced clinical status
of PDE4 inhibitors suggest that this might
be a profile worth seeking in drugs irre-
spective of molecular mechanism.
The discovery of PI3Kd/g inhibitors that
display up to 1,000-fold selectivity over0 ª2010 Elsevier Ltd All rights reservedPI3Ka/b is a worthy feat in itself, and
such compounds can head toward the
fraught trail of drug development, where
pharmaceutical properties of inhibitors
will also determine clinical progress.
By providing a BioMAP analysis, they
have demonstrated the favorable anti-
inflammatory properties against primary
human cells. This is a strong commenda-
tion of the potential therapeutic effect,
but not a replacement for whole human
body. Time will tell if taking these gang
leaders off the inflammatory paths will
make them safe.REFERENCES
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